-
Watch HOPE Summit 2026 Videos
HOPE Summit 2026 was filled with old friends reuniting, new friends being made, and of course, plenty of inspirational and informative sessions designed to help people live well with lung cancer.
For...
IN THE SPOTLIGHT
-
Clinical Trial Access Isn’t Expanding. It’s Concentrating.
Clinical trials show us whether a new treatment is safe and effective. They are also an important way for patients to access cutting-edge care. For trials to truly serve the lung... -
Podcast: Lung Cancer Diagnosis—What Happens Next
What happens after a lung cancer diagnosis? In this first episode of LUNGevity’s Lung Cancer Voices of Hope podcast, lung cancer survivor Lisa Bistline shares her experience, from... -
Podcast: Why Community Matters in Lung Cancer Care
Why does finding community matter in lung cancer care? In this episode, lung cancer survivor and advocate Jill Feldman shares her experience, from losing multiple family members to... -
Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss
This video is a recording from a LUNGevity virtual meetup. Each month, we host multiple virtual meetups for those impacted by lung cancer to meet and connect with others who... -
Weekly Virtual Meetup
For patients/survivors - Join us every Tuesday at 12 pm ET for this general meetup for anyone impacted by lung cancer. After registering, you will receive a confirmation email... -
Meet The “Mini-Organs” of Lung Cancer Research
Though many of us would like to deny it, our neighbors affect us. Their loud music disturbs our sleep. The scent of their dinner wafts through an open window. The sight of their... -
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung... -
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both...
Oncologist Perspectives on the CROWN Study – Lorlatinib in Stage III ALK-Positive NSCLC
Non-Small Cell Lung Cancer (NSCLC): Molecular Markers, Immune Therapy and Targeted Therapy
Non-Small Cell Lung Cancer (NSCLC): Molecular Markers, Immune Therapy and Targeted Therapy
聚焦 TP53 共突变：EGFR 突变 NSCLC 靶化联合治疗的精准决策_腾讯新闻
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
Prognostic significance of ypN status after neoadjuvant chemoimmunotherapy in resectable NSCLC: a systematic review and meta-analysis
Prognostic significance of ypN status after neoadjuvant chemoimmunotherapy in resectable NSCLC: a systematic review and meta-analysis
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting
Podcast: Making the Most of Your Healthcare Visits
Podcast: Making the Most of Your Healthcare Visits
How do you make the most of your visits with your healthcare team? In this episode, lung cancer survivor Bill Morris shares his experience with lung cancer and how he approaches his healthcare visits now. Oncology nurse practitioner Rasheda Persinger shares her insights after 20 years of working with patients. Hosts Ann and Dr. Shields discuss with Bill and Rasheda what they wish every patient knew, from writing down questions before an appointment to asking about biomarker testing to why…
Smart & Practical Tips From a Financial Navigator
Smart & Practical Tips From a Financial Navigator
LUNGevity offers a variety of virtual support groups called ‘meetups’ where lung cancer survivors and caregivers connect with others who understand the patient experience.Each month, an expert is invited to share information on a topic relevant to life with lung cancer, engage with attendees, and answer questions in real time. When the expert talk concludes, the focus shifts to survivor sharing and updates.The following video is a recording from a session with an expert during a LUNGevity…
Watch HOPE Summit 2026 Videos
Watch HOPE Summit 2026 Videos
HOPE Summit 2026 was filled with old friends reuniting, new friends being made, and of course, plenty of inspirational and informative sessions designed to help people live well with lung cancer.For the second year in a row, select sessions were recorded so those who could not attend are still able to access the valuable information shared.HOPE Summit 2026 Recorded Sessions Keynote: Wagons Roll with Dr. Ross Camidge Back in the Saddle: Reclaiming Strength and Living Well …
Clinical Trial Access Isn’t Expanding. It’s Concentrating.
Clinical Trial Access Isn’t Expanding. It’s Concentrating.
Clinical trials show us whether a new treatment is safe and effective. They are also an important way for patients to access cutting-edge care. For trials to truly serve the lung cancer community, the people who enroll in the trials need to represent the populations who are diagnosed in everyday life.Recognizing these needs, federal agencies like the United States Food and Drug Administration (FDA) have been encouraging clinical trials to offer more locations across the US.The PlanThe intention…
Podcast: Why Community Matters in Lung Cancer Care
Podcast: Why Community Matters in Lung Cancer Care
Why does finding community matter in lung cancer care? In this episode, lung cancer survivor and advocate Jill Feldman shares her experience, from losing multiple family members to lung cancer to her own diagnosis, as well as her work building patient communities around the world. She discusses how connecting with others has shaped her journey and why community is important for support, information, and advocacy.Hosts Ann Steagall, RN, BSN, and Misty Shields, MD, PhD, explore with Jill how…
Podcast: Lung Cancer Diagnosis—What Happens Next
Podcast: Lung Cancer Diagnosis—What Happens Next
What happens after a lung cancer diagnosis? In this first episode of LUNGevity’s Lung Cancer Voices of Hope podcast, lung cancer survivor Lisa Bistline shares her experience, from initial scans and biopsies through multiple treatments, and the moment a later biopsy revealed a biomarker that led to a targeted therapy.Hosts Ann Steagall and Misty Shields, MD, PhD, then speak with Anne Chiang, MD, PhD, thoracic oncologist at Yale University, about what patients can expect at their first visit,…
Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss
Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss
This video is a recording from a LUNGevity virtual meetup. Each month, we host multiple virtual meetups for those impacted by lung cancer to meet and connect with others who understand them and what they’re going through.Periodically, we invite an expert to speak on a topic at the beginning of a meetup, with the second half dedicated to questions and conversation. Visit the online calendar to see our virtual meetups and other upcoming events.For this meetup, we welcomed Jenna Doyle Ruhl and…
Meet The “Mini-Organs” of Lung Cancer Research
Meet The “Mini-Organs” of Lung Cancer Research
Though many of us would like to deny it, our neighbors affect us. Their loud music disturbs our sleep. The scent of their dinner wafts through an open window. The sight of their new puppy brings a smile. We interact with our environment every moment of the day. And so do lung cancer cells. A Brief HistoryTraditionally, we have studied tumor cells in isolation. We often study single cells in a petri dish, or under a microscope, to understand how they work. This has been very important and…
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung cancer care. Hosted by the International Association for the Study of Lung Cancer, this annual gathering was held in Huntington Beach, California from Feb. 18-21, 2026. It has become known as one of the key meetings for participants to discuss the latest breakthroughs and challenges in lung cancer.This year’s meeting…
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both encouraging news and a sobering reminder that our work is far from over.The Big Picture Shows Real ProgressLet’s start with the good news. We have made significant strides in cancer care over the past three decades. Since 1991, the cancer death rate has dropped by 34%. This translates to approximately 4.8 million…
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions.AI has evolved from early consumer tools (like autocorrect on phones, customer service chatbots, and personalized shopping recommendations) to advanced systems with the potential to revolutionize biomedical discovery and patient care. While there is tremendous excitement around AI, there is also a critical need to use it responsibly.Researchers are actively…
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting healthy tissue. But sometimes, the checks and balances get confused and stop the immune system from doing what’s right—such as killing tumor cells. Tumor cells are good at confusing the immune system because they originate from our healthy cells. They can often avoid detection by immune cells. Through several…
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused on multidisciplinary research aiming to leverage the immune system to improve outcomes for cancer patients, including several exciting areas of growth in lung cancer-directed immunotherapy.Tumor Imaging is Growing More Powerful Advanced imaging techniques are poised to change how we understand and treat…
The Future of Lung Cancer Starts Here
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects, helping to build a robust pipeline of discoveries in early detection, treatment innovation, and health equity.Once again, LUNGevity is ready to open our annual grant cycle in 2026 with five research programs designed to address the most pressing challenges in lung cancer care. In addition, these grants ensure the…
Biggest News from Berlin: Research Highlights from ESMO
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000 attendees from over 100 countries, this meeting gathered an international audience of clinicians, researchers, patient advocates, and representatives from the healthcare industry to discuss cutting-edge cancer research and share practice-changing clinical trial data. We saw data from studies that aim to build upon…
New Accelerated Approval for HER2-positive NSCLC
New Accelerated Approval for HER2-positive NSCLC
On November 19, 2025, the US Food and Drug Administration (FDA) announced the accelerated approval of sevabertinib (Hyrnuo®) to treat patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with specific mutations in the HER2 gene. This approval is for patients who have been previously treated with HER2-targeted therapies, as well as patients who have received previous treatment that did not target HER2.Mutations in the HER2 gene (also called the ERBB2 gene) are…
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum—from early detection to treating advanced disease.“Today’s research is tomorrow’s cure. If we want to see continued breakthroughs and advancements in lung cancer, we must secure a strong pipeline of researchers dedicated to improving outcomes for people with lung cancer,” said Upal Basu Roy, PhD, MPH, Executive Director…
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung cancer diagnosis. From groundbreaking early detection efforts to life-extending treatments, each step forward represents years of collaboration between researchers, patients, and others in the lung cancer community.Today, LUNGevity celebrates five exciting areas of progress that highlight the incredible strides made…
Veteran Voices: Surgery to Survivorship at the VA
Veteran Voices: Surgery to Survivorship at the VA
Last November, Michael O’Donnell was at the Dallas VA during Lung Cancer Awareness Month. It’s where he receives treatment for his lung cancer, but on this specific day, he was joined by LUNGevity staff to talk with veterans about screening.“My job was easy. I was at a table with Kristi Griffith [LUNGevity’s Survivorship Navigator] so that I could answer questions as someone who uses the VA to get treated for lung cancer,” says Michael. Michael is a veteran of the Vietnam War and uses the…
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
For people with advanced or metastatic non-small cell lung cancer (NSCLC), the treatment landscape has changed dramatically in recent years. Researchers are learning how to optimize existing therapies and are exploring entirely new treatment approaches. At the 2025 World Conference on Lung Cancer (WCLC), several studies highlighted progress in treating newly diagnosed individuals as well as those who need new options after standard therapies stop working. Combining Chemotherapy and…